The court denied this request. Exeltis is the New Drug Application (NDA) holder for SLYND®, four-milligram drospirenone tablets used as an oral contraceptive. The Orange Book listing for SLYND® ...
Today, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) ...